GKOS250117C90000
- 44.47
- 0.000.00%
Glaukos Newsroom
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
Glaukos Insider Sold Shares Worth $1,502,800, According to a Recent SEC Filing
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Express News | Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
The Three-year Returns Have Been Stellar for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153
NYSE New 52-Week Highs And Lows
Glaukos (GKOS) Receives a Buy From Stifel Nicolaus
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Announces Target Price $185
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Express News | Glaukos Corp : Jefferies Raises Target Price to $160 From $155
J.P. Morgan Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $160
Glaukos (GKOS) Receives a Buy From J.P. Morgan
Glaukos Is Maintained at Overweight by Wells Fargo
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153
Express News | Glaukos Corp : Citigroup Raises to Buy From Neutral
Wells Fargo Sticks to Its Buy Rating for Glaukos (GKOS)
Express News | Glaukos Corp. : Wells Fargo Raises Target Price to $153 From $145